Announced license agreement for Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs Q3 2021 cash position of $866.1 million SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial […]
Biotechnology
MAIA Biotechnology, Inc. Announces the Appointment of Steven M. Chaouki to Its Board of Directors
CHICAGO, September 28, 2021–(BUSINESS WIRE)–MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that it has appointed Steven M. Chaouki to its Board of Directors. Mr. Chaouki is a finance executive with over two decades of experience across capital markets and […]